AmEVs can function as immunotherapeutics to impede the progression of prostate cancer, primarily by activating the effector state of CD8+ T cells and facilitating the polarization of macrophages toward the M1 phenotype (101). The gene discussed is CD8A; the disease is prostate carcinoma.